肝癌患者外周血血小板活化标志物检测及临床意义

Markers of platelet activation in patients with liver cancer and their clinical significance

目的:探讨肝癌患者外周血血小板活化标志物水平变化的特点及临床意义。方法:采用流式细胞术(flowcytometry,FCM)检测35例肝癌患者外周血血小板活化标志物水平,并与40例健康体检者作对比分析。结果:肝癌患者外周血血小板活化标志物检测水平[单纯血小板活化水平:CD62P(2·44±1·50)%,CD63(2·02±1·22)%;黏附在细胞上的血小板活化水平:CD62P(18·42±12·18)%,CD63(19·37±12·73)%;外周血血小板总的活化水平:CD62P(3·43±1·80)%,CD63(2·94±1·50)%]明显高于正常对照组[单纯血小板活化水平:CD62P(1·04±0·45)%,CD63(0·64±0·29)%;黏附在细胞上的血小板活化水平:CD62P(2·19±0·85)%,CD63(3·23±1·64)%;外周血血小板总的活化水平:CD62P(1·48±0·40)%,CD63(1·29±0·35)%],差异有统计学意义,P值均为0.000。肝癌患者外周血血小板活化标志物水平受年龄、临床分期及肿瘤是否转移的影响,而不受性别的影响。结论:外周血血小板活化标志物水平可能成为监测肝癌患者病情进展的动态指标。

OBJECTIVE： To investigate the role of biological markers of platelet activation in peripheral blood and their association with clinicopathological variables in patients with liver cancer. METHODS： Levels of platelet activation markers in peripheral blood of 35 patients with liver cancer were measured by flow cytometry （FCM）. Forty healthy people served as a control group. RESULTS： Levels of platelet activation markers in peripheral blood of patients with liver cancer [levels of platelet activation markers not adhered to cell： CD62P（2.44±1.50）%, CD63（2.02±1.22）%; levels of platelet activation markers adhered to cell： CD62P（18.42±12.18）%, CD63（19.37±12.73）%; total levels of platelet activation markers in peripheral blood： CD62P（3.43±1.80）%, CD63（2.94±1.50）%] were significantly higher compared with the control group [levels of platelet activation markers not adhered to cell： CD62P（1.04±0.45）%, CD63（0.64±0.29）%; levels of platelet activation markers adhere to cell： CD62P（2.19±0.85）%, CD63（3.23±1.64）%; total levels of platelet activation markers in peripheral blood： CD62P（1.48±0.40）%, CD63（1.29±0.35）%]. All P values were 0.000. Levels of platelets activation markers in peripheral blood of patients with liver cancer were significantly associated with the age, clinical stage and metastasis. No significant differences were observed with respect to gender. CONCLUSION： Levels of platelet activation markers in peripheral blood may be used as a diagnostic tool for monitoring the progression of liver cancer.